{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:09:50Z","timestamp":1759972190445,"version":"build-2065373602"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal des Maladies Vasculaires"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.jmv.2008.10.009","type":"journal-article","created":{"date-parts":[[2008,12,25]],"date-time":"2008-12-25T05:29:47Z","timestamp":1230182987000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variabilit\u00e9 de r\u00e9ponse plaquettaire \u00e0 l\u2019aspirine et nouvelles cibles th\u00e9rapeutiques"],"prefix":"10.1016","volume":"34","author":[{"given":"S.","family":"Richard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Toussaint-Hacquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmv.2008.10.009_bib1","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jmv.2008.10.009_bib2","doi-asserted-by":"crossref","first-page":"s25","DOI":"10.1161\/ATVBAHA.107.160481","article-title":"Aspirin: promise and resistance in the new millenium","volume":"28","author":"Patrono","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jmv.2008.10.009_bib3","doi-asserted-by":"crossref","unstructured":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"10.1016\/j.jmv.2008.10.009_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jns.2004.11.023","article-title":"Aspirin resistance in stroke: 2004","volume":"229-230","author":"Sztriha","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jmv.2008.10.009_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncpcardio0728","article-title":"Drug insight: aspirin resistance. Fact or fashion?","volume":"4","author":"Patrono","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jmv.2008.10.009_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2008.10.009_bib7","first-page":"1627","article-title":"Antiplatelet agents and their therapeutic use","volume":"49","author":"Lecompte","year":"1999","journal-title":"Rev Prat"},{"key":"10.1016\/j.jmv.2008.10.009_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0014-2999(02)02956-4","article-title":"Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease","volume":"462","author":"Malinin","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jmv.2008.10.009_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2008.03.023","article-title":"Aspirin response evaluated by the VerifyNow\u00ae Aspirin System and Light Transmission Aggregometry","author":"Nielsen","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.STR.24.3.345","article-title":"Aspirin response and failure in cerebral infarction","volume":"24","author":"Helgason","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.jmv.2008.10.009_bib11","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.jmv.2008.10.009_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-J","article-title":"Two-year follow-up of aspirin responder and aspirin nonresponder. A pilot-study including 180 poststroke patients","volume":"71","author":"Grotemeyer","year":"1993","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jmv.2008.10.009_bib14","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2008.10.009_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00415-003-0954-y","article-title":"Aspirin nonresponder status in patients with recurrent cerebral ischemic attacks","volume":"250","author":"Grundmann","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.jmv.2008.10.009_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0091270007313324","article-title":"Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events","volume":"48","author":"Gengo","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jmv.2008.10.009_bib17","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis","volume":"167","author":"Snoep","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jmv.2008.10.009_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000103115","article-title":"Variable platelet response to aspirin in patients with ischemic stroke","volume":"24","author":"Hohlfeld","year":"2007","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jmv.2008.10.009_bib19","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1538-7836.2005.01633.x","article-title":"Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin","volume":"3","author":"Pulcinelli","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH05-07-0516","article-title":"Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients","volume":"95","author":"Lepantalo","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1538-7836.2006.01867.x","article-title":"Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers","volume":"4","author":"Fontana","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.STR.0000106763.46123.F6","article-title":"Antiplatelet effect of aspirin in patients with cerebrovascular disease","volume":"35","author":"Alberts","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jmv.2008.10.009_bib23","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jmv.2008.10.009_bib24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH05-10-0653","article-title":"Dose- and time-dependent antiplatelet effects of aspirin","volume":"95","author":"Perneby","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2008.10.009_bib26","first-page":"1589","article-title":"Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction","volume":"32","author":"Hudson","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jmv.2008.10.009_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.thromres.2003.12.005","article-title":"Mutations within the cyclooxygenase-1 gene in aspirin nonresponders with recurrence of stroke","volume":"112","author":"Hillarp","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib28","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.667584","article-title":"Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1","volume":"115","author":"Faraday","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2008.10.009_bib29","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/j.1538-7836.2005.01555.x","article-title":"Cyclooxygenase-1 haplotype modulates platelet response to aspirin","volume":"3","author":"Maree","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2003.1","article-title":"Genetic variation in cyclooxygenase 1: effects on response to aspirin","volume":"73","author":"Halushka","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jmv.2008.10.009_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0049-3848(00)00241-3","article-title":"Transcellular formation of thromboxane A(2) in mixed incubations of endothelial cells and aspirin-treated platelets strongly depends on the prostaglandin I synthase activity","volume":"99","author":"Camacho","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0049-3848(03)00382-7","article-title":"Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease","volume":"110","author":"Patrignani","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.ATV.0000104005.92603.f2","article-title":"Cyclooxygenase-2 expression and inhibition in atherothrombosis","volume":"24","author":"Cipollone","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jmv.2008.10.009_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ana.10612","article-title":"Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction","volume":"54","author":"Dore","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jmv.2008.10.009_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1022066305399","article-title":"Aspirin resistance and genetic polymorphisms","volume":"14","author":"Cambria-Kiely","year":"2002","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jmv.2008.10.009_bib36","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.89.5.1951","article-title":"Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin","volume":"89","author":"Larsson","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2008.10.009_bib37","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.CIR.100.13.1374","article-title":"Evidence for prothrombotic effects of exercise and limited protection by aspirin","volume":"100","author":"Li","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2008.10.009_bib38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0049-3848(00)00277-2","article-title":"Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin","volume":"99","author":"Hurlen","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/09537100500441101","article-title":"Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1\/2, a novel COX-1 polymorphism or the PlA(1\/2) polymorphism","volume":"17","author":"Kranzhofer","year":"2006","journal-title":"Platelets"},{"key":"10.1016\/j.jmv.2008.10.009_bib40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.STR.28.4.844","article-title":"Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles","volume":"28","author":"Hoffman","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.jmv.2008.10.009_bib41","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1054\/plef.2002.0399","article-title":"Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets","volume":"66","author":"Csiszar","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jmv.2008.10.009_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/01.CIR.0000043260.82447.62","article-title":"Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina","volume":"107","author":"Cipollone","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2008.10.009_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI115032","article-title":"Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment","volume":"87","author":"Santos","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jmv.2008.10.009_bib44","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/01.CIR.97.4.350","volume":"97","author":"Valles","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2008.10.009_bib45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2008.02915.x","article-title":"Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease","volume":"6","author":"Santos","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood.V78.1.154.154","article-title":"Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment","volume":"78","author":"Valles","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jmv.2008.10.009_bib47","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood.V99.11.3978","article-title":"Platelet\u2013erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: downregulation by aspirin ex vivo","volume":"99","author":"Valles","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jmv.2008.10.009_bib48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2141.2004.04983.x","article-title":"Platelet degranulation and monocyte\u2013platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack","volume":"125","author":"McCabe","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmv.2008.10.009_bib49","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1161\/01.RES.0000074030.98009.FF","article-title":"CD40-CD40L and platelet function: beyond hemostasis","volume":"92","author":"Freedman","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib50","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/01.RES.0000070111.98158.6C","article-title":"CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation","volume":"92","author":"Inwald","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib51","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.amjcard.2006.04.015","article-title":"Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population","volume":"98","author":"Faraday","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jmv.2008.10.009_bib52","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1538-7836.2004.00953.x","article-title":"Aspirin resistance in vitro and hypertension in stroke patients","volume":"2","author":"Macchi","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib53","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1161\/01.CIR.92.9.2432","article-title":"Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin","volume":"92","author":"Hung","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jmv.2008.10.009_bib54","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ahj.2004.08.030","article-title":"Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment","volume":"149","author":"Ikonomidis","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jmv.2008.10.009_bib55","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/01.ATV.16.8.948","article-title":"Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia","volume":"16","author":"Szczeklik","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jmv.2008.10.009_bib56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1742-7843.2006.pto_343.x","article-title":"Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to suboptimal platelet response to aspirin?","volume":"98","author":"Markuszewski","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jmv.2008.10.009_bib57","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.326.7380.82","article-title":"Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia","volume":"326","author":"Friend","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jmv.2008.10.009_bib58","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.295.12.1420","article-title":"Sex differences in platelet reactivity and response to low-dose aspirin therapy","volume":"295","author":"Becker","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jmv.2008.10.009_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00592-005-0186-y","article-title":"Prevalence of aspirin resistance in patients with type 2 diabetes","volume":"42","author":"Fateh-Moghadam","year":"2005","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jmv.2008.10.009_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2003.12.016","article-title":"Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): its relation to metabolic control","volume":"113","author":"Watala","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2008.10.009_bib61","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00109-004-0600-x","article-title":"Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin","volume":"8","author":"Watala","year":"2005","journal-title":"J Mol Med"},{"key":"10.1016\/j.jmv.2008.10.009_bib62","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jmv.2008.10.009_bib63","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00059-008-3129-x","article-title":"Aspirin \u201cResistance\u201d","volume":"33","author":"Zimmermann","year":"2008","journal-title":"Herz"},{"key":"10.1016\/j.jmv.2008.10.009_bib64","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ahj.2007.12.034","article-title":"Antiplatelet drug nonresponsiveness","volume":"155","author":"Gladding","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jmv.2008.10.009_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/107602960100700305","article-title":"Individual dosing of ASA prophylaxis by controlling platelet aggregation","volume":"7","author":"Syrbe","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib66","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1538-7836.2005.01468.x","article-title":"The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies","volume":"3","author":"Gaussem","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/14779072.5.1.45","article-title":"Platelet P2 receptors: old and new targets for antithrombotic drugs","volume":"5","author":"Cattaneo","year":"2007","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jmv.2008.10.009_bib68","doi-asserted-by":"crossref","unstructured":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329\u201339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"10.1016\/j.jmv.2008.10.009_bib69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0003-4509(07)90032-2","article-title":"Interindividual variability in the laboratory response to the aspirin\u2013clopidogrel combination: are patients with stent occlusion \u201cresistant\u201d to treatment?","volume":"65","author":"Hacquard","year":"2007","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.jmv.2008.10.009_bib70","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1160\/TH08-01-0049","article-title":"Clinical implications of clopidogrel resistance","volume":"100","author":"De Miguel","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib71","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2005.07.106","article-title":"Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention","volume":"97","author":"Angiolillo","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jmv.2008.10.009_bib72","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/pgmj.2006.047696","article-title":"Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study","volume":"82","author":"Serebruany","year":"2006","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jmv.2008.10.009_bib73","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"Antman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jmv.2008.10.009_bib74","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.ahj.2008.06.006","article-title":"Clinical overview of promising nonthienopyridine antiplatelet agents","volume":"156","author":"Angiolillo","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jmv.2008.10.009_bib75","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jmv.2008.10.009_bib76","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14017430410024324","article-title":"Unstable angina, stroke, myocardial infarction and death in aspirin nonresponders. A prospective, randomized trial. The ASCET (ASpirin nonresponsiveness and Clopidogrel Endpoint Trial) design","volume":"38","author":"Pettersen","year":"2004","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.jmv.2008.10.009_bib77","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jmv.2008.10.009_bib78","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10557-008-6121-z","article-title":"Tailoring treatment with tirofiban in patients showing resistance to aspirin and\/or resistance to clopidogrel (3T\/2R). Rationale for the study and protocol design","volume":"22","author":"Valgimigli","year":"2008","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jmv.2008.10.009_bib79","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1160\/TH07-08-0481","article-title":"Thrombin and protease-activated receptors (PARs) in atherothrombosis","volume":"99","author":"Martorell","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2008.10.009_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0404.1999.tb00658.x","article-title":"Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group","volume":"99","author":"Sivenius","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jmv.2008.10.009_bib81","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jmv.2008.10.009_bib82","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jmv.2008.10.009_bib83","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1159\/000089363","article-title":"Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives","volume":"20","author":"Bezerra","year":"2005","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jmv.2008.10.009_bib84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2005.08.058","article-title":"Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance","volume":"47","author":"Lev","year":"2006","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal des Maladies Vasculaires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039804990800406X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039804990800406X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:10:59Z","timestamp":1759954259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S039804990800406X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S039804990800406X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmv.2008.10.009","relation":{},"ISSN":["0398-0499"],"issn-type":[{"type":"print","value":"0398-0499"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variabilit\u00e9 de r\u00e9ponse plaquettaire \u00e0 l\u2019aspirine et nouvelles cibles th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"Journal des Maladies Vasculaires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmv.2008.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}